ArticlePharmacoEconomics2008
An overview of methods and applications to value informal care in economic evaluations of healthcare.
Article in PharmacoEconomics, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 109 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
109 citing papers in PubMed, 7 syntheses or guidelines pooled it.
- Economic Evaluations of Hearing Interventions in Older Adults: A Systematic Review of Evidence and Methods.Advances in therapy · 2026Pooled it
- A Systematic Review of Methods for Estimating Productivity Losses due to Illness or Caregiving in Low- and Middle-Income Countries.PharmacoEconomics · 2024Pooled it
- Economic evaluations in community aged care: a systematic review.BMC health services research · 2018Pooled it
- The Valuation of Informal Care in Cost-of-Illness Studies: A Systematic Review.PharmacoEconomics · 2017Pooled it
- Estimating productivity costs using the friction cost approach in practice: a systematic review.The European journal of health economics : HEPAC : health economics in prevention and care · 2016Pooled it
- Does including informal care in economic evaluations matter? A systematic review of inclusion and impact of informal care in cost-effectiveness studies.PharmacoEconomics · 2015Pooled it
- Disutility of illness for caregivers and families: a systematic review of the literature.PharmacoEconomics · 2013Pooled it
- Effectiveness of Escitalopram and Nortriptyline on Depressive Symptoms in Parkinson's disease: the ADepT-PD RCT pilot.Health technology assessment (Winchester, England) · 2025Trial
- Care-related quality of life of informal caregivers of stroke survivors: Cross-sectional analysis of a randomized clinical trial.PloS one · 2024Trial
- Assistive technology and telecare to maintain independent living at home for people with dementia: the ATTILA RCT.Health technology assessment (Winchester, England) · 2021Trial
- Cost-effectiveness of a non-pharmacological treatment vs. "care as usual" in day care centers for community-dwelling older people with cognitive impairment: results from the German randomized controlled DeTaMAKS-trial.The European journal of health economics : HEPAC : health economics in prevention and care · 2020Trial
- Trial
- Evaluation of the Prevention and Reactivation Care Program (PreCaP) for the hospitalized elderly: a prospective nonrandomized controlled trial.Clinical interventions in aging · 2015Trial
- Design of a cost-effectiveness analysis alongside a randomized trial of transplantation using umbilical cord blood versus HLA-haploidentical related bone marrow in advanced hematologic cancer.Journal of comparative effectiveness research · 2014Trial
- Trial
- Trial
- Individual Cognitive Stimulation Therapy for dementia (iCST): study protocol for a randomized controlled trial.Trials · 2012Trial
- Trial
- Private costs almost equal health care costs when intervening in mild Alzheimer's: a cohort study alongside the DAISY trial.BMC health services research · 2009Trial
- Economic Burden of Overweight and Obesity in Sweden: Current Estimates and Future Projections.Diabetes, obesity & metabolism · 2026Article
49 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This paper compares several applied valuation methods for including informal care in economic evaluations of healthcare programmes: the proxy good method; the opportunity cost method; the contingent valuation method (CVM); conjoint measurement (CM); and valuation of health effects in terms of health-related quality of life (HR-QOL) and well-being. The comparison focuses on three questions: what outcome measures are available for including informal care in economic evaluations of healthcare programmes; whether these measures are compatible with the common types of economic evaluation; and, when applying these measures, whether all relevant aspects of informal care are incorporated. All types of economic evaluation can incorporate a monetary value of informal care (using the opportunity cost method, the proxy good method, CVM and CM) on the cost side of an analysis, but only when the relevant aspects of time costs have been valued. On the effect side of a cost-effectiveness or cost-utility analysis, the health effects (for the patient and/or caregiver) measured in natural units or QALYs can be combined with cost estimates based on the opportunity cost method or the proxy good method. One should be careful when incorporating CVM and CM in cost-minimization, cost-effectiveness and cost-utility analyses, as the health effects of patients receiving informal care and the carers themselves may also have been valued separately. One should determine whether the caregiver valuation exercise allows combination with other valuation techniques. In cost-benefit analyses, CVM and CM appear to be the best tools for the valuation of informal care. When researchers decide to use the well-being method, we recommend applying it in a cost-benefit analysis framework. This method values overall QOL (happiness); hence it is broader than just HR-QOL, which complicates inclusion in traditional health economic evaluations that normally define outcomes more narrowly. Using broader, non-monetary valuation techniques, such as the CarerQol instrument, requires a broader evaluation framework than cost-effectiveness/cost-utility analysis, such as cost-consequence or multi-criteria analysis.
Indexed as
Identifiers
18370563What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.